COMMENTARY: Review: Ursodeoxycholic acid does not reduce risk for mortality or liver transplantation in primary biliary cirrhosis
- Review: Ursodeoxycholic acid does not reduce risk for mortality or liver transplantation in primary biliary cirrhosis. // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p17
The article presents a study which examines the effect of ursodeoxycholic acid (UDCA) in treating patients with primary biliary cirrhosis (PBC). Quality assessment of individual trials was based on randomization method. In patients with PBC, study shows that UDCA does not reduce risk for...
- Secondary sclerosing cholangitis rapidly leading to liver cirrhosis: a possible post-ICU treatment sequel. Reichert, M. C.; Jüngst, C.; Grünhage, F.; Lammert, F.; Krawczyk, M. // QJM: An International Journal of Medicine;Feb2016, Vol. 109 Issue 2, p119
No abstract available.
- Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial Papatheodoridis, George V.; Hadziyannis, Emilia S.; Deutsch, Melanie; Hadziyannis, Stephanos J. // American Journal of Gastroenterology;Aug2002, Vol. 97 Issue 8, p2063
OBJECTIVES:The aim of this study was to evaluate whether ursodeoxycholic acid (UDCA) has any effect on the development of liver decompensation and on survival of patients with primary biliary cirrhosis (PBC).METHODS:A total of 86 patients with compensated PBC were randomly assigned to receive...
- Immunosuppressants. // Reactions Weekly;1/12/2008, Issue 1184, p22
The article describes the case of a male liver transplant recipient, who experienced recurrence of intestinal schistosomiasis following ciclosporin withdrawal. At the age of 57 years, the patient underwent liver transplantation for cirrhosis secondary to schistosomiasis. He had received...
- Biliary atresia. Chardot, Christophe // Orphanet Journal of Rare Diseases;2006, Vol. 1, p28
Biliary atresia (BA) is a rare disease characterised by a biliary obstruction of unknown origin that presents in the neonatal period. It is the most frequent surgical cause of cholestatic jaundice in this age group. BA occurs in approximately 1/18,000 live births in Western Europe. In the world,...
- To TOE or not to TOE? That is the question in patients with portal hypertension and varices. Leung, Christopher; Sern Wei Yeoh; Lim, Lucy Y.; Boyapati, Ray; Testro, Adam G.; Vaughan, Rhys; Marion, Kaye; Burrell, Louise M.; Angus, Peter W. // Gut;Apr2013, Vol. 62 Issue 4, p655
A letter to the editor is presented in response to the article "Management of patients with cirrhosis awaiting liver transplantation" by A Cardenas and P. Gines in the 2011 issue.
- Liver transplantation in patients with alcoholic cirrhosis: selection criteria and rates of survival and relapse. Bird, George I.A.; O'Grady, John G.; Harvey, Felicity A.H.; Calne, Roy Y.; Williams, Roger // BMJ: British Medical Journal (International Edition);7/1/90, Vol. 301 Issue 6742, p15
Evaluates the outcome of liver transplantation in patients with alcoholic cirrhosis in England. Percentage of the survival rate of patients in one year; Criteria for the selection of liver transplantation in patients; Indication of the return to drinking by patients.
- Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Fried, Ronald H.; Murakami, Carol S.; Fisher, Lloyd D.; Willson, Richard A.; Sullivan, Keith M.; McDonald, George B.; Fried, R H; Murakami, C S; Fisher, L D; Willson, R A; Sullivan, K M; McDonald, G B // Annals of Internal Medicine;4/15/92, Vol. 116 Issue 8, p624
Objective:To determine the safety and efficacy of ursodeoxycholic acid treatment in patients with chronic graft-versus-host disease (GVHD) of the liver. Design:Open-label study in which each patient served as his or her own control. Setting:Private...
- Results of long-term ursodiol treatment for patients with primary biliary cirrhosis Jorgensen, Roberta; Angulo, Paul; Dickson, E. Rolland; Lindor, Keith D. // American Journal of Gastroenterology;Oct2002, Vol. 97 Issue 10, p2647
OBJECTIVE:When ursodeoxycholic acid (UDCA) is used for the treatment of primary biliary cirrhosis, it has been associated with biochemical improvement, histological stability, reduced risk of esophageal varices, and increased survival free of transplantation. There is limited information...